Compare SoFi Technologies Inc (SOFI) vs TG Therapeutics Inc (TGTX) Price & Performance

SoFi Technologies trades at $18.01, down 1.15% amid mixed signals. The stock shows strong fundamental progress with 40% revenue growth and three consecutive earnings beats, though Q3 2026 expectations of $0.17 EPS present a high bar. Technical indicators are neutral with support at $18 and resistance at $19. Recent partnership with Payward expands banking infrastructure capabilities while rising Treasury yields pressure fintech lenders.

SoFi presents a growth story with expanding profitability and strategic partnerships, though negative operating cash flow and high valuation multiples warrant caution. Analyst consensus targets $20.78 with 37% buy ratings, suggesting moderate upside potential balanced against macroeconomic sensitivity and competitive pressures in the digital banking space.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.